Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803
Publication: Journal of Clinical Oncology
Abstract
Purpose
Regular physical activity reduces the risk of developing colon cancer, however, its influence on patients with established disease is unknown.
Patients and Methods
We conducted a prospective observational study of 832 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on various recreational physical activities approximately 6 months after completion of therapy and were observed for recurrence or death. To minimize bias by occult recurrence, we excluded patients who experienced recurrence or died within 90 days of their physical activity assessment.
Results
Compared with patients engaged in less than three metabolic equivalent task (MET) -hours per week of physical activity, the adjusted hazard ratio for disease-free survival was 0.51 (95% CI, 0.26 to 0.97) for 18 to 26.9 MET-hours per week and 0.55 (95% CI, 0.33 to 0.91) for 27 or more MET-hours per week. The adjusted P for trend was .01. Postdiagnosis activity was associated with similar improvements in recurrence-free survival (P for trend = .03) and overall survival (P for trend = .01). The benefit associated with physical activity was not significantly modified by sex, body mass index, number of positive lymph nodes, age, baseline performance status, or chemotherapy received. Moreover, the benefit remained unchanged even after excluding participants who developed cancer recurrence or died within 6 months of activity assessment.
Conclusion
Beyond surgical resection and postoperative adjuvant chemotherapy for stage III colon cancer, for patients who survive and are recurrence free approximately 6 months after adjuvant chemotherapy, physical activity appears to reduce the risk of cancer recurrence and mortality.
Introduction
Physically active people have a reduced risk of developing colon cancer.1-11 A meta-analysis of 19 cohort studies showed a statistically significant 22% reduction in the risk of colon cancer in active males and 29% reduction in active females.12 Several biologic mechanisms have been proposed for this association, including decreasing circulating levels of insulin and free insulinlike growth factor-1 (IGF-1); decreasing central deposition of adipose tissue; and altering prostaglandin synthesis, bile acid secretion, and gut flora.13 The insulin–colon cancer hypothesis has generated the most attention.13-15 Both insulin and IGF-1 promote cell proliferation and inhibit apoptosis in colon cancer cells.16-19 Colon cancer risk is elevated in individuals with higher circulating levels of insulin or C-peptide20-22 and IGF-1.23-27 Recent reports suggest that patients with colorectal cancer and lower IGF-binding protein-3 (which decreases circulating IGF-1) may have inferior survival.28,29
Beyond cancer incidence, few studies have assessed the impact of physical activity on the survival of patients after diagnosis.30 Recent data suggest that physical activity may reduce cancer recurrences and mortality among patients treated for early breast cancer31 and prostate cancer.32 Whether physical activity influences recurrence or survival rates among patients with colon cancer remains uncertain.
We examined the association of exercise on cancer recurrences and survival after surgery and chemotherapy for stage III colon cancer. Within a large clinical trial of adjuvant chemotherapy sponsored by the National Cancer Institute (NCI), we prospectively assessed physical activity approximately 6 months after completion of postoperative chemotherapy and monitored patients thereafter for cancer recurrence.33
Patients and Methods
Study Population
Patients in this prospective cohort study were participants in the NCI-sponsored Cancer and Leukemia Group B (CALGB) adjuvant therapy trial for stage III colon cancer comparing therapy with weekly fluorouracil and leucovorin to weekly irinotecan, fluorouracil, and leucovorin (CALGB 89803).33 Between April 1999 and May 2001, 1,264 patients were enrolled onto the treatment trial. A self-administered questionnaire capturing diet and lifestyle habits was given to patients midway through their adjuvant therapy (4 months after surgical resection) and again 6 months after completion of adjuvant therapy (14 months after surgical resection). Given that an amendment to the protocol to survey diet/lifestyle was activated after the first 87 patients were enrolled, only the subsequent 1,177 patients were eligible for the diet and lifestyle study. Figure 1 illustrates the compliance with completion of questionnaires 1 (midway through adjuvant therapy) and 2 (approximately 6 months after completion of adjuvant therapy) and reasons for ineligibility at various time points. The final sample size for this study was 832.
Patients in the treatment trial were eligible if they underwent a complete surgical resection of the primary tumor within 56 days of study entry and had regional lymph node metastases (stage III colon cancer) but no evidence of distant metastases. Moreover, patients were required to have a baseline Eastern Cooperative Oncology Group performance status of 0 to 2 (ambulatory)34,35 and have adequate bone marrow, renal, and hepatic function. All patients signed informed consent, approved by the internal review board of the local institution.
Physical Activity Assessment
The physical activity questions used have been validated extensively and described previously.31,36,37 Briefly, participants were asked, “During the past 2 months, what was your average time per week spent at each of the following recreational activities?” Patients reported duration of participation (ranging from 0 to 11 or more hours per week) in walking, jogging, running, bicycling, swimming laps, racket sports, other aerobic exercises, lower intensity exercise (yoga, toning, stretching), or other vigorous activities. In addition, participants were asked the number of flights of stairs climbed daily and their usual walking pace (slow, < 2 miles per hour [mph]; normal or average, 2 to 2.9 mph; brisk, 3 to 3.9 mph; very brisk, ≥ 4 mph; or unable to walk).
Each activity on the questionnaire was assigned a metabolic equivalent task (MET) score (Table 1) 38 One MET is the energy expenditure for sitting quietly for 1 hour. MET scores for walking were assigned based on the pace reported; for other activities, a leisurely to moderate intensity score was selected. The scores for MET-hours per week for each activity were calculated from the reported hours per week engaged in that activity multiplied by the assigned MET score, and individual activities were summed to derive a total MET-hours per week. Categories of MET-hours per week were defined as less than 3, 3 to 8.9, 9 to 17.9, 18 to 26.9, and 27 or more, chosen to correspond to the equivalent of less than 1, 1 to less than 3, 3 to less than 6, 6 to less than 9, and 9 or more hours per week of walking at an average pace, consistent with prior analyses.39
For these analyses, we used the physical activity assessment collected on the second questionnaire (approximately 6 months after completion of adjuvant therapy) to avoid measurements during the period of active treatment. The median time from completion of chemotherapy to assessment was 7.1 months. The median time from study entry (which had to be within 8 weeks of surgery) was 13.4 months. Only patients who did not experience recurrence or die before the second questionnaire were included in these analyses. To avoid biases due to declining physical activity immediately before recurrence or death, we also excluded patients who experienced either event within 90 days of the physical activity assessment (46 patients).
Study End Points
In this ancillary study, the primary end point was disease-free survival (DFS), defined as time from the completion of the second questionnaire to tumor recurrence, occurrence of a new primary colon tumor, or death as a result of any cause. In addition, we defined recurrence-free survival (RFS) as the time from the completion of the second questionnaire to tumor recurrence or occurrence of a new primary colon tumor. For RFS, patients who died without known tumor recurrence were censored at the last documented evaluation by the treating provider. Finally, overall survival (OS) was defined as the time from the completion of the second questionnaire to death as a result of any cause.
Statistical Analyses
During interim analysis of the treatment trial (comparing two chemotherapy regimens), it was determined that no difference in either DFS or OS would be observed between the treatment arms.33 Thus, data for patients in both treatment arms were combined and analyzed according to categories of physical activity. DFS, RFS, and OS were examined using Kaplan and Meier curves and the log-rank test.40 Cox proportional hazards regression41 was used to determine the simultaneous impact of potential confounders. Covariates with missing variables were coded with indicator variables in adjusted models. The less than 3 MET-hours per week category was the reference group. Tests for linear trend across categories were calculated by using the median value of each category of physical activity (total MET-hours per week) as a continuous variable in a proportional hazards model, consistent with prior studies.3,31 The degree of nonlinearity was evaluated using a penalized Cox model and smoothing splines.40 A level of significance less than .05 was considered statistically significant. Tests of interactions between physical activity categories and potentially modifying covariates were assessed by entering the cross product of the physical activity (dichotomized at 18 total MET-hours per week) and the dichotomized covariate. We used SAS version 9.1 (SAS Institute, Cary, NC) and S-Plus version 7.0 (Insightful Corp, Seattle, WA) for all statistical analyses. All P values are two sided and were not adjusted for multiple comparisons.
Patient registration and clinical data collection were managed by the CALGB Statistical Center and all analyses were based on the study database frozen on March 18, 2005.
Results
Baseline Characteristics by Physical Activity Category
Study participants were drawn from a multicenter study of postoperative adjuvant chemotherapy in patients with stage III colon cancer who underwent a curative-intent surgical resection. Baseline characteristics of the 832 patients in this analysis are shown in Table 2. Patients with higher activity tended to be male, leaner, and younger, although the median body mass index for each activity category was still in the overweight range (body mass index, 25 to 30 kg/m2). Similarly, although physically active patients experienced less weight gain after diagnosis, patients in each activity category gained a median of at least 2 kg, and at least 75% of patients in each category experienced weight gain. There was a trend toward an increased level of physical activity with a higher baseline performance status (measured at the time of initiation of adjuvant therapy). Although this difference did not reach statistical significance (P = .06), we did adjust for this factor in multivariate analyses as well as stratify for performance status. In contrast, other characteristics, particularly tumor characteristics known to predict prognosis, did not differ significantly across physical activity categories.
Cancer Recurrences and Survival by Level of Physical Activity
The median follow-up from the time of completion of the second questionnaire was 2.7 years (10th and 90th percentiles were 1.7 and 3.6 years, respectively). However, given that the median follow-up from study entry for these patients was 3.8 years, most colon cancer recurrences would be anticipated by this time. In total, 159 of the 832 patients included in this analysis had cancer recurrence and 84 patients died (either with or without recurrent disease).
The predefined, primary study end point of this analysis was DFS (time to cancer recurrence or death as a result of any cause). Higher postdiagnosis physical activity among patients who survived without disease progression 3 months after completion of the questionnaire was associated with a significant reduction in the risk of cancer recurrence or mortality (Fig 2), and this relation remained largely unchanged after adjusting for other predictors of cancer recurrence (Table 3). Compared with patients who reported less than 3 total MET-hours per week of activity, those reporting 18 to 26.9 total MET-hours per week had a multivariate hazard ratio of 0.51 (95% CI, 0.26 to 0.97) and those with greater than 27 total MET-hours per week had a hazard ratio of 0.55 (95% CI, 0.33 to 0.91; P for trend = .01).
To isolate the influence of physical activity on cancer recurrences, we used the end point RFS and confirmed that physical activity conferred a significant reduction in cancer recurrence (P for trend = .03; Table 3). Finally, although OS follow-up for this study remains active, we observed a significant inverse relation between physical activity and all-cause mortality, after adjusting for other predictors of survival (P for trend = .01; Table 3).
Given that lower levels of physical activity could reflect occult cancer or impending death, we excluded patients who developed cancer recurrence or died within 90 days of completing the physical activity assessment in our primary analyses. To address this issue further, we repeated the Cox proportional hazards models after excluding patients who developed cancer recurrence or died within 180 days of completing the physical activity assessment. Although statistical power was somewhat diminished by this more stringent exclusion, our results remained largely unchanged. Increasing physical activity was still associated with a decreased risk of cancer recurrence or death (adjusted DFS; P for trend = .02). Moreover, the adjusted linear tests for trend for cancer recurrence (RFS) and overall mortality (OS) were .05 and .06, respectively.
The Kaplan-Meier curves (Fig 2) suggest a difference in DFS among patients reporting MET-hours above and below 18 total MET-hours per week. Collapsing activity levels into two categories (< 18 and ≥ 18 total MET-hours per week), as suggested by Figure 2, those with at least 18 total MET-hours per week had a hazard ratio of 0.57 (95% CI, 0.39 to 0.85), compared with those engaging in less than 18 MET-hours per week. The 3-year DFS (from the time of questionnaire completion) was 75.1% for patients who engage in less than 18 MET-hours per week and 84.5% for patients who engage in 18 or more MET-hours per week. To better characterize the amount of activity necessary to have a benefit, we generated a smoothing spline of log hazard versus the log of the total MET score (Fig 3), a method independent of predetermined MET-hour categorizations. A log hazard less than zero represents a favorable hazard ratio (< 1). The spline suggests the protective hazard ratio may occur at approximately 9 total MET-hours per week or sooner. Furthermore, the slope of the curve beyond 27 total MET-hours per week suggests that there is a threshold beyond which additional exercise does not lead to further improvements in DFS.
Stratified Analyses by Potential Effect Modifiers
We examined the influence of physical activity across strata of other predictors of cancer recurrence and mortality (Fig 4). Calculation of adjusted hazard ratios and 95% CIs comparing 18 or more to less than 18 MET-hours per week showed that the reduced risk of cancer recurrence or death was apparent in all subgroups defined on the basis of prognostic factors at entry into the treatment trial. The effect of physical activity was not significantly modified by sex, body mass index, number of positive lymph nodes, age, baseline performance status, or treatment arm.
Discussion
In a cohort of patients with stage III colon cancer treated with surgery and adjuvant chemotherapy surviving without recurrence 6 months after chemotherapy, physical activity after diagnosis was associated with a significant reduction in cancer recurrence and overall mortality. Patients who engaged in at least 18 MET-hours per week of activity (the equivalent of walking 6 or more hours per week at an average pace) had a statistically significant 47% improvement in DFS, compared with inactive patients.
Physical activity has been shown consistently to affect colon cancer incidence,1-11 though no studies have been reported on physical activity after the diagnosis of colon cancer. Haydon et al42 reported that prediagnosis physical activity was not associated with colorectal cancer–specific survival.
There are several advantages of using a cohort within a NCI-sponsored clinical trial. First, all patients had lymph node–positive cancer, reducing the impact of heterogeneity by disease stage. Second, treatment and follow-up care are standardized, and the date and nature of recurrence are recorded prospectively. Finally, detailed information on other prognostic variables is collected routinely.
Patients who enroll in randomized trials may differ from the population at large. To participate, a patient must meet eligibility criteria, be selected as an appropriate candidate, and be motivated to participate. However, we did observe reasonable variability in exercise levels among participants. Moreover, because the study included patients throughout North America, as well as both community and academic centers, our findings should reflect the general population of stage III patients.
We cannot exclude completely the possibility that lower levels of physical activity may be reflective of other occult predictors for poor prognosis. However, we did not observe any significant association between physical activity and other predictors associated with cancer recurrence or survival. Given that patients were enrolled onto a clinical trial, they all initiated fluorouracil-based adjuvant chemotherapy after surgery. Moreover, the benefit associated with exercise remained largely unchanged across the number of positive lymph nodes as well as baseline performance status. Furthermore, we considered the possibility that sick patients (with cancer recurrences and limited survival) will exercise less. To minimize this bias, we excluded recurrences or deaths within 90 days of the physical activity assessment in the primary analysis. Furthermore, we continue to see a positive impact of exercise even when we extended this restriction to exclude events 6 months after physical activity assessment. Finally, because all patients were observed on a clinical trial with prescribed follow-up visits and testing, we would expect few patients to have undetected recurrences over extended periods of time, given the relatively brief natural history of recurrent colon cancer.
Patients who underwent treatment for colon cancer may be considered limited in their ability to exercise. However, Arndt et al43 reported that 1 year after surgery of the primary tumor, patients with colorectal cancer reported that their physical functioning and global quality of life was nearly identical to those of a noncancer population. Furthermore, the distribution of levels of recreational activity are consistent with those seen in noncancer populations.3,11
Given that patients who are more physically active after cancer diagnosis may have been similarly active before diagnosis, we cannot exclude the possibility that active individuals who develop colon cancer acquire tumors that are biologically less aggressive. Nonetheless, as stated above, we did not observe any significant association between physical activity and tumor-related characteristics associated with cancer recurrences. Moreover, in a recent study of colorectal cancer survival nested within the Nurses' Health Study, prediagnosis physical activity among those women diagnosed with colorectal cancer did not influence colorectal cancer–specific or overall mortality, whereas physical activity after diagnosis also conferred a significant reduction in cancer mortality.44
An important caveat to these results is that patients included in the analysis remained disease free and alive 14 months after surgery (6 months after completion of adjuvant chemotherapy). Although we believe that this approach is the most appropriate to measure an ongoing lifestyle habit after the effects of cancer treatment resolve, a limitation is that the data do not address the role of exercise before that time period (ie, immediately after treatment).
Physical activity was self-reported in this study. However, the questions have been validated previously 36,37 and shown to be predictive of other health outcomes, including cardiovascular,45,46 cancer,3,32,47,48 and total mortality.49,50 Furthermore, exercise levels were recorded before any knowledge of colon cancer–related outcomes, thus reducing the likelihood of reporting biases.
Studies have shown an improved DFS among patients who receive adjuvant chemotherapy after the surgical resection of stage III colon cancer. These findings along with data from the Nurses' Health Study cohort suggest that exercise may confer additional improvements in cancer survival beyond surgery and chemotherapy. Efforts are underway to determine the optimal way to promote exercise in cancer survivors51; once such interventions are established, our data support the need for a randomized trial in colon cancer survivors.
Appendix
The following institutions participated in this study: Baptist Cancer Institute CCOP, Memphis, TN–Lee S. Schwartzberg, MD, supported by CA71323; CALGB Statistical Center, Durham, NC–Stephen George, PhD, supported by CA33601; Christiana Care Health Services Inc CCOP, Wilmington, DE–Stephen Grubbs, MD, supported by CA45418; Dana-Farber Cancer Institute, Boston, MA–George P. Canellos, MD, supported by CA32291; Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH–Marc S. Ernstoff, MD, supported by CA04326; Duke University Medical Center, Durham, NC–Jeffrey Crawford, MD, supported by CA47577; Georgetown University Medical Center, Washington, DC, Edward Gelmann, MD, supported by CA77597; Cancer Centers of the Carolinas, Greenville, SC–Jeffrey K. Giguere, MD, supported by CA29165; Massachusetts General Hospital, Boston, MA–Michael L. Grossbard, MD, supported by CA12449; Memorial Sloan-Kettering Cancer Center, New York, NY, Clifford Hudis, MD, supported by CA77651; Missouri Baptist Medical Center, St Louis, MO–Alan P. Lyss, MD, no specific support; Mount Sinai Medical Center, Miami, FL–Rogerio Lilenbaum, MD, supported by CA45564; Mount Sinai School of Medicine, New York, NY–Lewis R. Silverman, MD, supported by CA04457; North Shore Long Island Jewish Medical Center, Manhasset, NY–Daniel R Budman, MD, supported by CA35279; Rhode Island Hospital, Providence, RI–William Sikov, MD, supported by CA08025; Roswell Park Cancer Institute, Buffalo, NY–Ellis Levine, MD, supported by CA02599; Southeast Cancer Control Consortium Inc, CCOP, Goldsboro, NC–James N. Atkins, MD, supported by CA45808; Southeast Cancer Control Consortium Inc, CCOP, Goldsboro, NC–James N. Atkins, MD, supported by CA45808; Southern Nevada Cancer Research Foundation CCOP, Las Vegas, NV–John Ellerton, MD, supported by CA35421; SUNY Upstate Medical University, Syracuse, NY–Stephen L. Graziano, MD, supported by CA21060; Syracuse Hematology-Oncology Assoc CCOP, Syracuse, NY–Jeffrey Kirshner, MD, supported by CA45389; The Ohio State University Medical Center, Columbus, OH–Clara D. Bloomfield, MD, supported by CA77658; University of California at San Diego, San Diego, CA–Stephen L. Seagren, MD, supported by CA11789; University of California at San Francisco, San Francisco, CA–Alan P. Venook, MD, supported by CA60138; University of Chicago Medical Center, Chicago, IL –Gini Fleming, MD, supported by CA41287; University of Illinois MBCCOP, Chicago, IL–Lawrence E. Feldman, MD, supported by CA74811; University of Iowa, Iowa City, IA–Gerald Clamon, MD, supported by CA47642; University of Maryland Greenebaum Cancer Center, Baltimore, MD–Martin Edelman, MD, supported by CA31983; University of Massachusetts Medical Center, Worcester, MA–William V. Walsh, MD, supported by CA37135; University of Minnesota, Minneapolis, MN–Bruce A. Peterson, MD, supported by CA16450; University of Missouri/Ellis Fischel Cancer Center, Columbia, MO–Michael C. Perry, MD, supported by CA12046; University of Nebraska Medical Center, Omaha, NE–Anne Kessinger, MD, supported by CA77298; University of North Carolina at Chapel Hill, Chapel Hill, NC–Thomas C. Shea, MD, supported by CA47559; University of Tennessee Memphis, Memphis, TN–Harvey B. Niell, MD, supported by CA47555; Vermont Cancer Center, Burlington, VT–Hyman B. Muss, MD, supported by CA77406; Wake Forest University School of Medicine, Winston-Salem, NC–David D. Hurd, MD, supported by CA03927; Walter Reed Army Medical Center, Washington, DC–Thomas Reid, MD, supported by CA26806; Washington University School of Medicine, St Louis, MO–Nancy Bartlett, MD, supported by CA77440; Weill Medical College of Cornell University, New York, NY–Scott Wadler, MD, supported by CA07968.
Authors' Disclosures of Potential Conflicts of Interest
The authors indicated no potential conflicts of interest.
Author Contributions
Conception and design: Jeffrey A. Meyerhardt, Donna Niedzwiecki, Leonard B. Saltz, Robert J. Mayer, Richard Schilsky, Charles S. Fuchs
Financial support: Jeffrey A. Meyerhardt, Richard L. Schilsky, Charles S. Fuchs
Administrative support: Denise Heseltine, Donna Hollis
Provision of study materials or patients: Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, James Thomas, Heidi Nelson, Renaud Whittom, Alexander Hantel, Richard L. Schilsky, Charles S. Fuchs
Collection and assembly of data: Jeffrey A. Meyerhardt, Denise Heseltine, Donna Niedzwiecki, Donna Hollis, Charles S. Fuchs
Data analysis and interpretation: Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Charles S. Fuchs
Manuscript writing: Jeffrey A. Meyerhardt, Donna Hollis, Charles S. Fuchs
Final approval of manuscript: Jeffrey A. Meyerhardt, Denise Heseltine, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, James Thomas, Heidi Nelson, Renaud Whittom, Alexander Hantel, Richard L. Schilsky, Charles S. Fuchs
| Leisure-Time Activity | MET-Hours |
|---|---|
| Normal pace walking (2 to 2.9 mph) | 3 |
| Brisk pace walking (3 to 3.9 mph) | 4 |
| Very brisk pace walking (4+ mph) | 4.5 |
| Jogging (slower than 10 min/mile) | 7 |
| Running (faster than 10 min/mile) | 12 |
| Bicycling | 7 |
| Tennis, squash, racquetball | 7 |
| Lap swimming | 7 |
| Calisthenics, ski or stair machine, other aerobic exercise | 6 |
| Yoga, stretching, toning, lower intensity exercise | 4 |
| Other vigorous activities (lawn mowing) | 6 |
Abbreviations: MET, metabolic equivalent task; mph, miles per hour.
| Characteristic | Total MET-Hours per Week | P* | No. With Missing Variable | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 3 | 3-8.9 | 9-17.9 | 18-26.9 | ≥ 27 | |||||||
| No. of patients | 273 | 187 | 137 | 84 | 151 | ||||||
| Median MET-hours per week | 0.6 | 5.9 | 13.3 | 21.5 | 42.6 | 0 | |||||
| Male, % | 44 | 57 | 64 | 67 | 66 | < .0001 | 0 | ||||
| Median age, years | 61 | 61 | 59 | 59 | 59 | .05† | 0 | ||||
| Race or ethnicity | .055 | 3 | |||||||||
| White | 83 | 92 | 94 | 93 | 92 | ||||||
| African American | 11 | 5 | 3 | 5 | 4 | ||||||
| Other | 6 | 3 | 3 | 2 | 4 | ||||||
| Median body mass index, kg/m2 (at time of second questionnaire) | 29.8 | 28.6 | 27.9 | 28.5 | 27.3 | .0002† | 5 | ||||
| Median weight change,‡ kg | +3.6 | +3.6 | +3.6 | +3.2 | +2.0 | .006† | 5 | ||||
| Baseline PS,§ % | .06 | 24 | |||||||||
| 0 | 71 | 76 | 83 | 77 | 81 | ||||||
| 1-2 | 29 | 24 | 17 | 23 | 19 | ||||||
| Invasion through bowel wall (T stage)‖ | .92 | 24 | |||||||||
| T1-2 | 15 | 15 | 14 | 18 | 17 | ||||||
| T3-4 | 85 | 85 | 86 | 82 | 83 | ||||||
| No. of positive lymph nodes, % | .14 | 22 | |||||||||
| 1-3 (N1) | 74 | 63 | 69 | 64 | 66 | ||||||
| 4+ (N2) | 26 | 37 | 31 | 36 | 34 | ||||||
| Clinical bowel perforation, % | 5 | 3 | 1 | 6 | 3 | .33 | 32 | ||||
| Clinical bowel obstruction, % | 24 | 24 | 19 | 15 | 25 | .38 | 24 | ||||
| Postoperative CEA > 5 ng/dL, % | 5 | 4 | 4 | 4 | 5 | .95 | 63 | ||||
| Grade of differentiation, % | .11 | 23 | |||||||||
| Well | 9 | 3 | 4 | 5 | 5 | ||||||
| Moderate | 69 | 78 | 76 | 72 | 68 | ||||||
| Poor | 22 | 19 | 20 | 23 | 27 | ||||||
| Treatment arm, % | .99 | 0 | |||||||||
| FU/LV | 50 | 49 | 52 | 50 | 50 | ||||||
| IFL | 50 | 51 | 48 | 50 | 50 | ||||||
NOTE. Age, performance status, and postoperative CEA based on patient's status at initiation of chemotherapy (entry into the treatment trial).
Abbreviations: MET, metabolic equivalent task; CEA, carcinoembryonic antigen; PS, performance status; FU, fluorouracil; LV, leucovorin; IFL, irinotecan, FU, and leucovorin.
*
By χ2 test unless otherwise noted.
†
By Wilcoxon rank sum.
‡
Change of weight between questionnaire 1 (within 4 months of surgery) and questionnaire 2 (around 6 months after completion of chemotherapy).
§
PS 0, fully active; PS 1, restricted in physically strenuous activity but ambulatory and able to carry out light work; PS 2, ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours.
‖
T1-2, level of invasion through the bowel wall not beyond the muscle layer; T3-4, level of invasion through the bowel wall beyond the muscle layer.
| Outcome | Total MET-Hours per Week | P for Trend | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 3 | 3-8.9 | 9-17.9 | 18-26.9 | ≥ 27 | ||||||||||||||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |||||||||||
| Cancer recurrence or death from any cause (disease-free survival) | ||||||||||||||||||||
| No. of events | 67 | 42 | 30 | 11 | 22 | |||||||||||||||
| No. at risk | 273 | 187 | 137 | 84 | 151 | |||||||||||||||
| Unadjusted | Referent | 0.94 | 0.64 to 1.38 | 0.89 | 0.58 to 1.37 | 0.51 | 0.27 to 0.97 | 0.58 | 0.36 to 0.94 | .01 | ||||||||||
| Adjusted* | Referent | 0.87 | 0.58 to 1.29 | 0.90 | 0.57 to 1.40 | 0.51 | 0.26 to 0.97 | 0.55 | 0.33 to 0.91 | .01 | ||||||||||
| Cancer recurrence (recurrence-free survival) | ||||||||||||||||||||
| No. of events | 62 | 38 | 27 | 10 | 22 | |||||||||||||||
| No. at risk | 273 | 187 | 137 | 84 | 151 | |||||||||||||||
| Unadjusted | Referent | 0.92 | 0.61 to 1.37 | 0.87 | 0.55 to 1.37 | 0.50 | 0.26 to 0.98 | 0.63 | 0.39 to 1.02 | .03 | ||||||||||
| Adjusted* | Referent | 0.86 | 0.57 to 1.30 | 0.89 | 0.55 to 1.42 | 0.51 | 0.26 to 1.01 | 0.60 | 0.36 to 1.01 | .03 | ||||||||||
| Overall mortality | ||||||||||||||||||||
| No. of events | 33 | 21 | 13 | 8 | 9 | |||||||||||||||
| No. at risk | 273 | 187 | 137 | 84 | 151 | |||||||||||||||
| Unadjusted | Referent | 0.93 | 0.53 to 1.60 | 0.75 | 0.39 to 1.43 | 0.79 | 0.37 to 1.72 | 0.50 | 0.24 to 1.04 | .05 | ||||||||||
| Adjusted* | Referent | 0.85 | 0.49 to 1.49 | 0.71 | 0.36 to 1.41 | 0.71 | 0.32 to 1.59 | 0.37 | 0.16 to 0.82 | .01 | ||||||||||
Abbreviations: MET, metabolic equivalent task; HR, hazard ratio; CEA, carcinoembryonic antigen.
*
Adjusted for sex, age, depth of invasion through bowel wall (T1-2 v T3-4), number of positive lymph nodes (one to three v four or more), presence of clinical perforation at time of surgery, presence of bowel obstruction at time of surgery, baseline CEA (≤ 5 v > 5 ng/dL), grade of tumor differentiation (poorly or undifferentiated v well or moderately), baseline performance status (0 v 1-2), treatment arm, weight change between first and second questionnaire, body mass index at time of second questionnaire, and time between study entry and completion of second questionnaire.
Supported in part by the National Cancer Institute (Grant No. CA31946) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman) and Pharmacia & Upjohn Company, now Pfizer Oncology. Supported in part by a K07 award from the National Cancer Institute (Grant No. 1K07CA097992-01A1) and an American Society of Clinical Oncology Career Development Award (J.A.M.).
Article contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
References
1.
Lee IM, Paffenbarger RS Jr, Hsieh C: Physical activity and risk of developing colorectal cancer among college alumni. J Natl Cancer Inst 83::1324,1991-1329,
2.
Gerhardsson M, Floderus B, Norell SE: Physical activity and colon cancer risk. Int J Epidemiol 17::743,1988-746,
3.
Martinez ME, Giovannucci E, Spiegelman D, et al: Leisure-time physical activity, body size, and colon cancer in women: Nurses' Health Study Research Group. J Natl Cancer Inst 89::948,1997-955,
4.
Wu AH, Paganini-Hill A, Ross RK, et al: Alcohol, physical activity and other risk factors for colorectal cancer: A prospective study. Br J Cancer 55::687,1987-694,
5.
Thun MJ, Calle EE, Namboodiri MM, et al: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84::1491,1992-1500,
6.
Ballard-Barbash R, Schatzkin A, Albanes D, et al: Physical activity and risk of large bowel cancer in the Framingham Study. Cancer Res 50::3610,1990-3613,
7.
Albanes D, Blair A, Taylor PR: Physical activity and risk of cancer in the NHANES I population. Am J Public Health 79::744,1989-750,
8.
Severson RK, Nomura AM, Grove JS, et al: A prospective analysis of physical activity and cancer. Am J Epidemiol 130::522,1989-529,
9.
Lynge E, Thygesen L: Use of surveillance systems for occupational cancer: Data from the Danish National system. Int J Epidemiol 17::493,1988-500,
10.
Paffenbarger RS Jr, Hyde RT, Wing AL: Physical activity and incidence of cancer in diverse populations: A preliminary report. Am J Clin Nutr 45::312,1987-317,
11.
Giovannucci E, Ascherio A, Rimm EB, et al: Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122::327,1995-334,
12.
Samad AK, Taylor RS, Marshall T, et al: A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis 7::204,2005-213,
13.
Kaaks R, Lukanova A: Energy balance and cancer: The role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60::91,2001-106,
14.
Sandhu MS, Dunger DB, Giovannucci EL: Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94::972,2002-980,
15.
Giovannucci E: Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 131::3109S,2001-3120S,
16.
Pollak MN, Perdue JF, Margolese RG, et al: Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 38::223,1987-230,
17.
Guo YS, Narayan S, Yallampalli C, et al: Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology 102::1101,1992-1108,
18.
Koenuma M, Yamori T, Tsuruo T: Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 80::51,1989-58,
19.
Bjork J, Nilsson J, Hultcrantz R, et al: Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol 28::879,1993-884,
20.
Schoen RE, Tangen CM, Kuller LH, et al: Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91::1147,1999-1154,
21.
Kaaks R, Toniolo P, Akhmedkhanov A, et al: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92::1592,2000-1600,
22.
Palmqvist R, Stattin P, Rinaldi S, et al: Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: A prospective study in northern Sweden. Int J Cancer 107::89,2003-93,
23.
Palmqvist R, Hallmans G, Rinaldi S, et al: Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: A prospective study in northern Sweden. Gut 50::642,2002-646,
24.
Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91::620,1999-625,
25.
Manousos O, Souglakos J, Bosetti C, et al: IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 83::15,1999-17,
26.
Renehan AG, Painter JE, Atkin WS, et al: High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 88::107,2001-113,
27.
Giovannucci E, Pollak MN, Platz EA, et al: A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9::345,2000-349,
28.
Haydon AM, Macinnis RJ, English DR, et al: Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut 55::689,2006-694,
29.
Fuchs C, Pollak M, Sargent D, et al: Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741. J Clin Oncol 22::250s,2004, (suppl; abstr 3521)
30.
Brown JK, Byers T, Doyle C, et al: Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices. CA Cancer J Clin 53::268,2003-291,
31.
Holmes MD, Chen WY, Feskanich D, et al: Physical activity and survival after breast cancer diagnosis. JAMA 293::2479,2005-2486,
32.
Giovannucci EL, Liu Y, Leitzmann MF, et al: A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 165::1005,2005-1010,
33.
Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol 22::245s,2004, (suppl; abstr 3500)
34.
Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5::649,1982-655,
35.
Weeks J: Quality-of-life assessment: Performance status upstaged? J Clin Oncol 10::1827,1992-1829,
36.
Chasan-Taber S, Rimm EB, Stampfer MJ, et al: Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7::81,1996-86,
37.
Wolf AM, Hunter DJ, Colditz GA, et al: Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 23::991,1994-999,
38.
Ainsworth BE, Haskell WL, Leon AS, et al: Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 25::71,1993-80,
39.
Colditz GA, Feskanich D, Chen WY, et al: Physical activity and risk of breast cancer in premenopausal women. Br J Cancer 89::847,2003-851,
40.
Therneau T, Grambsch P: Modeling Survival Data . New York, NY, Springer, 2000
41.
Jones MP, Crowley J: A general class of nonparametric tests for survival analysis. Biometrics 45::157,1989-170,
42.
Haydon AM, Macinnis R, English D, et al: The effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55::62,2006-67,
43.
Arndt V, Merx H, Stegmaier C, et al: Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: A population-based study. J Clin Oncol 22::4829,2004-4836,
44.
Meyerhardt JA, Giovannucci EL, Holmes MD, et al: Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24::3527,2006-3535,
45.
Hu FB, Stampfer MJ, Solomon C, et al: Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 134::96,2001-105,
46.
Hu FB, Stampfer MJ, Colditz GA, et al: Physical activity and risk of stroke in women. JAMA 283::2961,2000-2967,
47.
Rockhill B, Willett WC, Hunter DJ, et al: A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med 159::2290,1999-2296,
48.
Michaud DS, Giovannucci E, Willett WC, et al: Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 286::921,2001-929,
49.
Rockhill B, Willett WC, Manson JE, et al: Physical activity and mortality: A prospective study among women. Am J Public Health 91::578,2001-583,
50.
Hu FB, Willett WC, Li T, et al: Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 351::2694,2004-2703,
51.
Centers for Behavioral and Preventive Medicine: Physical Activity Research Center. .http://www.lifespan.org/BehavMed/researchphysical.htm
Information & Authors
Information
Published In
Copyright
© 2006 by American Society of Clinical Oncology.
History
Published in print: August 01, 2006
Published online: September 21, 2016
Authors
Metrics & Citations
Metrics
Altmetric
Citations
Article Citation
Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. JCO 24, 3535-3541(2006).
Download Citation
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Journal of Clinical Oncology 2006 24:22, 3535-3541
Journal of Clinical Oncology 2006 24:22, 3535-3541
View Options
View options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.
Subscribe
Subscribe to this Journal
Renew Your Subscription
Become a Member